{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T01:14:03Z","timestamp":1789953243608,"version":"4.0.1"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s12020-019-01895-z","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T09:23:53Z","timestamp":1552555433000},"page":"14-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Novel PET tracers: added value for endocrine disorders"],"prefix":"10.1007","volume":"64","author":[{"given":"S\u00e9bastien","family":"Bergeret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Charbit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ansquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Bera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lussey-Lepoutre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"1895_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"R. Boellaard, R. Delgado-Bolton, W.J.G. Oyen et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med Mol. Imaging 42, 328\u2013354 (2015). \n                    https:\/\/doi.org\/10.1007\/s00259-014-2961-x","journal-title":"Eur. J. Nucl. Med Mol. Imaging"},{"key":"1895_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/jcp.25478","volume":"232","author":"V Cuccurullo","year":"2017","unstructured":"V. Cuccurullo, G.D. Di Stasio, L. Evangelista, G. Castoria, L. Mansi, Biochemical and pathophysiological premises to positron emission tomography with Choline radiotracers. J. Cell. Physiol. 232, 270\u2013275 (2017). \n                    https:\/\/doi.org\/10.1002\/jcp.25478","journal-title":"J. Cell. Physiol."},{"key":"1895_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.mednuc.2016.01.003","volume":"40","author":"C Lussey-Lepoutre","year":"2016","unstructured":"C. Lussey-Lepoutre, E. Hindi\u00e9, F. Montravers et al. The current role of 18F-FDOPA PET for neuroendocrine tumor imaging. M\u00e9decine Nucl. 40, 20\u201330 (2016). \n                    https:\/\/doi.org\/10.1016\/j.mednuc.2016.01.003","journal-title":"M\u00e9decine Nucl."},{"issue":"Suppl 1","key":"1895_CR4","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1530\/ERC-10-0282","volume":"18","author":"JJM Teunissen","year":"2011","unstructured":"J.J.M. Teunissen, D.J. Kwekkeboom, R. Valkema, E.P. Krenning, Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr. Relat. Cancer 18(Suppl 1), S27\u2013S51 (2011). \n                    https:\/\/doi.org\/10.1530\/ERC-10-0282","journal-title":"Endocr. Relat. Cancer"},{"key":"1895_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","volume":"9","author":"IM Modlin","year":"2008","unstructured":"I.M. Modlin, K. Oberg, D.C. Chung et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9, 61\u201372 (2008). \n                    https:\/\/doi.org\/10.1016\/S1470-2045(07)70410-2","journal-title":"Lancet Oncol."},{"key":"1895_CR6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.annpat.2011.01.001","volume":"31","author":"JY Scoazec","year":"2011","unstructured":"J.-Y. Scoazec, A. Couvelard, Ppour le r\u00e9seau TENpath (r\u00e9seau national d\u2019expertise pour le diagnostic anatomopathologique des tumeurs neuroendocrines malignes de l\u2019adulte, sporadiques et familiales). [The new WHO classification of digestive neuroendocrine tumors]. Ann. Pathol. 31, 88\u201392 (2011). \n                    https:\/\/doi.org\/10.1016\/j.annpat.2011.01.001","journal-title":"Ann. Pathol."},{"key":"1895_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cncr.27716","volume":"119","author":"A Dolcetta-Capuzzo","year":"2013","unstructured":"A. Dolcetta-Capuzzo, V. Villa, L. Albarello et al. Gastroenteric neuroendocrine neoplasms classification: comparison of prognostic models. Cancer 119, 36\u201344 (2013). \n                    https:\/\/doi.org\/10.1002\/cncr.27716","journal-title":"Cancer"},{"key":"1895_CR8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000481390","volume":"33","author":"G Kl\u00f6ppel","year":"2017","unstructured":"G. Kl\u00f6ppel, Neuroendocrine neoplasms: dichotomy, origin and classifications. Visc. Med. 33, 324\u2013330 (2017). \n                    https:\/\/doi.org\/10.1159\/000481390","journal-title":"Visc. Med."},{"key":"1895_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"J. Strosberg, G. El-Haddad, E. Wolin et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N. Engl. J. Med. 376, 125\u2013135 (2017). \n                    https:\/\/doi.org\/10.1056\/NEJMoa1607427","journal-title":"N. Engl. J. Med."},{"key":"1895_CR10","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.2967\/jnumed.117.191197","volume":"58","author":"MM Graham","year":"2017","unstructured":"M.M. Graham, X. Gu, T. Ginader, P. Breheny, J.J. Sunderland, 68Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and metaanalysis. J. Nucl. Med. 58, 1452\u20131458 (2017). \n                    https:\/\/doi.org\/10.2967\/jnumed.117.191197","journal-title":"J. Nucl. Med."},{"key":"1895_CR11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2967\/jnumed.115.165803","volume":"57","author":"SA Deppen","year":"2016","unstructured":"S.A. Deppen, J. Blume, A.J. Bobbey et al. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J. Nucl. Med. 57, 872\u2013878 (2016). \n                    https:\/\/doi.org\/10.2967\/jnumed.115.165803","journal-title":"J. Nucl. Med."},{"key":"1895_CR12","first-page":"1455","volume":"47","author":"F Montravers","year":"2006","unstructured":"F. Montravers, D. Grahek, K. Kerrou et al. Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? J. Nucl. Med. 47, 1455\u20131462 (2006)","journal-title":"J. Nucl. Med."},{"key":"1895_CR13","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2967\/jnumed.113.126896","volume":"55","author":"A Imperiale","year":"2014","unstructured":"A. Imperiale, E. Rust, S. Gabriel et al. 18F-fluorodihydroxyphenylalanine PET\/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation. J. Nucl. Med. 55, 367\u2013372 (2014). \n                    https:\/\/doi.org\/10.2967\/jnumed.113.126896","journal-title":"J. Nucl. Med."},{"issue":"Suppl 2","key":"1895_CR14","doi-asserted-by":"publisher","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","volume":"58","author":"M Fani","year":"2017","unstructured":"M. Fani, G.P. Nicolas, D. Wild, Somatostatin receptor antagonists for imaging and therapy. J. Nucl. Med. 58(Suppl 2), 61S\u201366S (2017). \n                    https:\/\/doi.org\/10.2967\/jnumed.116.186783","journal-title":"J. Nucl. Med."},{"key":"1895_CR15","doi-asserted-by":"publisher","first-page":"915","DOI":"10.2967\/jnumed.117.199760","volume":"59","author":"GP Nicolas","year":"2018","unstructured":"G.P. Nicolas, N. Schreiter, F. Kaul et al. Sensitivity comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET\/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospective phase II imaging study. J. Nucl. Med. 59, 915\u2013921 (2018). \n                    https:\/\/doi.org\/10.2967\/jnumed.117.199760","journal-title":"J. Nucl. Med."},{"key":"1895_CR16","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","volume":"19","author":"TR Halfdanarson","year":"2008","unstructured":"T.R. Halfdanarson, K.G. Rabe, J. Rubin, G.M. Petersen, Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann. Oncol. J. Eur. Soc. Med Oncol. 19, 1727\u20131733 (2008). \n                    https:\/\/doi.org\/10.1093\/annonc\/mdn351","journal-title":"Ann. Oncol. J. Eur. Soc. Med Oncol."},{"key":"1895_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1148\/radiology.195.2.7724749","volume":"195","author":"H Ahlstr\u00f6m","year":"1995","unstructured":"H. Ahlstr\u00f6m, B. Eriksson, M. Bergstr\u00f6m, P. Bjurling, B. L\u00e5ngstr\u00f6m, K. Oberg, Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology 195, 333\u2013337 (1995). \n                    https:\/\/doi.org\/10.1148\/radiology.195.2.7724749","journal-title":"Radiology"},{"key":"1895_CR18","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1210\/jc.2008-1349","volume":"94","author":"F Montravers","year":"2009","unstructured":"F. Montravers, K. Kerrou, V. Nataf et al. Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors. J. Clin. Endocrinol. Metab. 94, 1295\u20131301 (2009). \n                    https:\/\/doi.org\/10.1210\/jc.2008-1349","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1895_CR19","doi-asserted-by":"publisher","first-page":"7183","DOI":"10.1158\/0008-5472.CAN-08-0095","volume":"68","author":"OC Neels","year":"2008","unstructured":"O.C. Neels, K.P. Koopmans, P.L. Jager et al. Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells. Cancer Res. 68, 7183\u20137190 (2008). \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0095","journal-title":"Cancer Res."},{"key":"1895_CR20","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1200\/JCO.2008.18.8581","volume":"26","author":"S Kauhanen","year":"2008","unstructured":"S. Kauhanen, M. Sepp\u00e4nen, P. Nuutila, Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomography. J. Clin. Oncol. Oncol. 26, 5307\u20135308 (2008). \n                    https:\/\/doi.org\/10.1200\/JCO.2008.18.8581\n                    \n                  . author reply5308-5309","journal-title":"J. Clin. Oncol. Oncol."},{"key":"1895_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00259-014-2943-z","volume":"42","author":"A Imperiale","year":"2015","unstructured":"A. Imperiale, F. Sebag, M. Vix et al. 18F-FDOPA PET\/CT imaging of insulinoma revisited. Eur. J. Nucl. Med. Mol. Imaging 42, 409\u2013418 (2015). \n                    https:\/\/doi.org\/10.1007\/s00259-014-2943-z","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR22","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/RLU.0000000000000686","volume":"40","author":"A Imperiale","year":"2015","unstructured":"A. Imperiale, T. Bahougne, B. Goichot, P. Bachellier, D. Ta\u00efeb, I.J. Namer, Dynamic 18F-FDOPA PET findings after carbidopa premedication in 2 adult patients with insulinoma-related hyperinsulinemic hypoglycemia. Clin. Nucl. Med. 40, 682\u2013684 (2015). \n                    https:\/\/doi.org\/10.1097\/RLU.0000000000000686","journal-title":"Clin. Nucl. Med."},{"key":"1895_CR23","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1210\/jc.2013-1942","volume":"98","author":"A Imperiale","year":"2013","unstructured":"A. Imperiale, P. Addeo, G. Averous, I.J. Namer, P. Bachellier, Solid pseudopapillary pancreatic tumor mimicking a neuroendocrine neoplasm on 18F-FDOPA PET\/CT. J. Clin. Endocrinol. Metab. 98, 2643\u20132644 (2013). \n                    https:\/\/doi.org\/10.1210\/jc.2013-1942","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1895_CR24","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1007\/s00330-011-2199-y","volume":"21","author":"R Kumar","year":"2011","unstructured":"R. Kumar, P. Sharma, P. Garg et al. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur. Radiol. 21, 2408\u20132416 (2011). \n                    https:\/\/doi.org\/10.1007\/s00330-011-2199-y","journal-title":"Eur. Radiol."},{"key":"1895_CR25","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00259-013-2371-5","volume":"40","author":"C Schmid-Tannwald","year":"2013","unstructured":"C. Schmid-Tannwald, C.M. Schmid-Tannwald, J.N. Morelli et al. Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET\/CT in detection of neuroendocrine tumors of the pancreas. Eur. J. Nucl. Med. Mol. Imaging 40, 897\u2013907 (2013). \n                    https:\/\/doi.org\/10.1007\/s00259-013-2371-5","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00261-014-0219-5","volume":"40","author":"P Sharma","year":"2015","unstructured":"P. Sharma, S. Arora, V.S. Dhull et al. Evaluation of (68)Ga-DOTANOC PET\/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors. Abdom. Imaging 40, 299\u2013309 (2015). \n                    https:\/\/doi.org\/10.1007\/s00261-014-0219-5","journal-title":"Abdom. Imaging"},{"key":"1895_CR27","first-page":"69","volume":"60","author":"P Sharma","year":"2016","unstructured":"P. Sharma, S. Arora, S. Karunanithi et al. Somatostatin receptor based PET\/CT imaging with 68Ga-DOTA-Nal3-octreotide for localization of clinically and biochemically suspected insulinoma. Q J. Nucl. Med Mol. Imaging 60, 69\u201376 (2016)","journal-title":"Q J. Nucl. Med Mol. Imaging"},{"key":"1895_CR28","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00259-016-3331-7","volume":"43","author":"V Prasad","year":"2016","unstructured":"V. Prasad, A. Sainz-Esteban, R. Arsenic et al. Role of (68)Ga somatostatin receptor PET\/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study. Eur. J. Nucl. Med. Mol. Imaging 43, 1593\u20131600 (2016). \n                    https:\/\/doi.org\/10.1007\/s00259-016-3331-7","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR29","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1210\/jc.2002-021895","volume":"88","author":"J Bertherat","year":"2003","unstructured":"J. Bertherat, F. Tenenbaum, K. Perlemoine et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J. Clin. Endocrinol. Metab. 88, 5353\u20135360 (2003). \n                    https:\/\/doi.org\/10.1210\/jc.2002-021895","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1895_CR30","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2967\/jnumed.115.167445","volume":"57","author":"Y Luo","year":"2016","unstructured":"Y. Luo, Q. Pan, S. Yao et al. Glucagon-like peptide-1 receptor PET\/CT with 68Ga-NOTA-exendin-4 for detecting localized insulinoma: a prospective cohort study. J. Nucl. Med. 57, 715\u2013720 (2016). \n                    https:\/\/doi.org\/10.2967\/jnumed.115.167445","journal-title":"J. Nucl. Med."},{"key":"1895_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(13)70049-4","volume":"1","author":"E Christ","year":"2013","unstructured":"E. Christ, D. Wild, S. Ederer et al. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes Endocrinol. 1, 115\u2013122 (2013). \n                    https:\/\/doi.org\/10.1016\/S2213-8587(13)70049-4","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1895_CR32","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1007\/s00259-018-4101-5","volume":"45","author":"K Antwi","year":"2018","unstructured":"K. Antwi, M. Fani, T. Heye et al. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET\/CT, SPECT\/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study. Eur. J. Nucl. Med. Mol. Imaging 45, 2318\u20132327 (2018). \n                    https:\/\/doi.org\/10.1007\/s00259-018-4101-5","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00259-008-1030-8","volume":"36","author":"A Haug","year":"2009","unstructured":"A. Haug, C.J. Auernhammer, B. W\u00e4ngler et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 36, 765\u2013770 (2009). \n                    https:\/\/doi.org\/10.1007\/s00259-008-1030-8","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR34","first-page":"68","volume":"54","author":"D Putzer","year":"2010","unstructured":"D. Putzer, M. Gabriel, D. Kendler et al. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q J. Nucl. Med Mol. Imaging 54, 68\u201375 (2010)","journal-title":"Q J. Nucl. Med Mol. Imaging"},{"key":"1895_CR35","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1007\/s00261-012-9925-z","volume":"38","author":"N Naswa","year":"2013","unstructured":"N. Naswa, P. Sharma, R. Soundararajan et al. Diagnostic performance of somatostatin receptor PET\/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. Abdom. Imaging 38, 552\u2013560 (2013). \n                    https:\/\/doi.org\/10.1007\/s00261-012-9925-z","journal-title":"Abdom. Imaging"},{"key":"1895_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00292-013-1888-5","volume":"35","author":"M Anlauf","year":"2014","unstructured":"M. Anlauf, B. Sipos, I. Boeck et al. [Neuroendocrine neoplasms of the distal jejunum and ileum]. Pathology 35, 283\u2013293 (2014). \n                    https:\/\/doi.org\/10.1007\/s00292-013-1888-5\n                    \n                  . quiz 294","journal-title":"Pathology"},{"key":"1895_CR37","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00259-013-2342-x","volume":"40","author":"S Balogova","year":"2013","unstructured":"S. Balogova, J.-N. Talbot, V. Nataf et al. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur. J. Nucl. Med. Mol. Imaging 40, 943\u2013966 (2013). \n                    https:\/\/doi.org\/10.1007\/s00259-013-2342-x","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR38","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/S1470-2045(06)70801-4","volume":"7","author":"KP Koopmans","year":"2006","unstructured":"K.P. Koopmans, E.G.E. de Vries, I.P. Kema et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 7, 728\u2013734 (2006). \n                    https:\/\/doi.org\/10.1016\/S1470-2045(06)70801-4","journal-title":"Lancet Oncol."},{"key":"1895_CR39","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1245\/s10434-014-3981-2","volume":"22","author":"H Ilhan","year":"2015","unstructured":"H. Ilhan, W.P. Fendler, C.C. Cyran et al. Impact of (68)Ga-DOTATATE PET\/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum. Ann. Surg. Oncol. 22, 164\u2013171 (2015). \n                    https:\/\/doi.org\/10.1245\/s10434-014-3981-2","journal-title":"Ann. Surg. Oncol."},{"key":"1895_CR40","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00259-008-0769-2","volume":"35","author":"V Ambrosini","year":"2008","unstructured":"V. Ambrosini, P. Tomassetti, P. Castellucci et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 35, 1431\u20131438 (2008). \n                    https:\/\/doi.org\/10.1007\/s00259-008-0769-2","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR41","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2967\/jnumed.109.069765","volume":"51","author":"T Binderup","year":"2010","unstructured":"T. Binderup, U. Knigge, A. Loft et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J. Nucl. Med.51, 704\u2013712 (2010). \n                    https:\/\/doi.org\/10.2967\/jnumed.109.069765","journal-title":"J. Nucl. Med."},{"key":"1895_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s13139-017-0496-3","volume":"52","author":"TH Tan","year":"2018","unstructured":"T.H. Tan, C.Y. Boey, B.N. Lee, Impact of 68Ga-DOTA-peptide PET\/CT on the management of gastrointestinal neuroendocrine tumour (GI-NET): Malaysian National Referral Centre Experience. Nucl. Med. Mol. Imaging 52, 119\u2013124 (2018). \n                    https:\/\/doi.org\/10.1007\/s13139-017-0496-3","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"1895_CR43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/00006231-200208000-00005","volume":"23","author":"T Belhocine","year":"2002","unstructured":"T. Belhocine, J. Foidart, P. Rigo et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl. Med. Commun. 23, 727\u2013734 (2002)","journal-title":"Nucl. Med. Commun."},{"key":"1895_CR44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1102\/1470-7330.2012.0026","volume":"12","author":"E Rust","year":"2012","unstructured":"E. Rust, F. Hubele, E. Marzano et al. Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice. Cancer Imaging. 12, 173\u2013184 (2012). \n                    https:\/\/doi.org\/10.1102\/1470-7330.2012.0026","journal-title":"Cancer Imaging."},{"key":"1895_CR45","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1210\/jc.2010-2022","volume":"96","author":"R Abgral","year":"2011","unstructured":"R. Abgral, S. Leboulleux, D. D\u00e9andreis et al. Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (\u2009\u2265\u200910%) well-differentiated endocrine carcinoma staging. J. Clin. Endocrinol. Metab. 96, 665\u2013671 (2011). \n                    https:\/\/doi.org\/10.1210\/jc.2010-2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1895_CR46","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.3892\/ijo.2014.2570","volume":"45","author":"G Luo","year":"2014","unstructured":"G. Luo, Z. Liu, M. Guo et al. (18)F-FDG PET\/CT can be used to detect non-functioning pancreatic neuroendocrine tumors. Int. J. Oncol. 45, 1531\u20131536 (2014). \n                    https:\/\/doi.org\/10.3892\/ijo.2014.2570","journal-title":"Int. J. Oncol."},{"key":"1895_CR47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1159\/000368609","volume":"100","author":"S Partelli","year":"2014","unstructured":"S. Partelli, M. Rinzivillo, A. Maurizi et al. The role of combined Ga-DOTANOC and (18)FDG PET\/CT in the management of patients with pancreatic neuroendocrine tumors. Neuroendocrinology 100, 293\u2013299 (2014). \n                    https:\/\/doi.org\/10.1159\/000368609","journal-title":"Neuroendocrinology"},{"key":"1895_CR48","doi-asserted-by":"publisher","first-page":"858","DOI":"10.2967\/jnumed.108.057505","volume":"50","author":"E Garin","year":"2009","unstructured":"E. Garin, F. Le Jeune, A. Devillers et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J. Nucl. Med. 50, 858\u2013864 (2009). \n                    https:\/\/doi.org\/10.2967\/jnumed.108.057505","journal-title":"J. Nucl. Med."},{"key":"1895_CR49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1159\/000480239","volume":"106","author":"M Bucau","year":"2018","unstructured":"M. Bucau, A. Laurent-Bellue, N. Pot\u00e9 et al. 18F-FDG uptake in well-differentiated neuroendocrine tumors correlates with both Ki-67 and VHL pathway inactivation. Neuroendocrinology 106, 274\u2013282 (2018). \n                    https:\/\/doi.org\/10.1159\/000480239","journal-title":"Neuroendocrinology"},{"key":"1895_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3109\/0284186X.2015.1067715","volume":"55","author":"EM Tabaksblat","year":"2016","unstructured":"E.M. Tabaksblat, S.W. Langer, U. Knigge et al. Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: state of the art. Acta Oncol. Stockh. Swed. 55, 3\u201314 (2016). \n                    https:\/\/doi.org\/10.3109\/0284186X.2015.1067715","journal-title":"Acta Oncol. Stockh. Swed."},{"key":"1895_CR51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/cncr.23542","volume":"113","author":"BI Gustafsson","year":"2008","unstructured":"B.I. Gustafsson, M. Kidd, A. Chan, M.V. Malfertheiner, I.M. Modlin, Bronchopulmonary neuroendocrine tumors. Cancer 113, 5\u201321 (2008). \n                    https:\/\/doi.org\/10.1002\/cncr.23542","journal-title":"Cancer"},{"key":"1895_CR52","unstructured":"C. Ansquer, D. Taieb, F. Montravers, F. Tenenbaum, PET imaging with 68 gallium labelled somatostatin analogues in the evaluation of neuroendocrine tumours (NETs). \n                    http:\/\/www.em-consulte.com\/en\/article\/963107\n                    \n                  . Accessed 16 June 2018."},{"key":"1895_CR53","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"MF Bozkurt","year":"2017","unstructured":"M.F. Bozkurt, I. Virgolini, S. Balogova et al. Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur. J. Nucl. Med. Mol. Imaging 44, 1588\u20131601 (2017). \n                    https:\/\/doi.org\/10.1007\/s00259-017-3728-y","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR54","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s00259-005-0020-3","volume":"33","author":"M Rodrigues","year":"2006","unstructured":"M. Rodrigues, T. Traub-Weidinger, S. Li, B. Ibi, I. Virgolini, Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 33, 532\u2013540 (2006). \n                    https:\/\/doi.org\/10.1007\/s00259-005-0020-3","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/MNM.0b013e32832999c1","volume":"30","author":"V Ambrosini","year":"2009","unstructured":"V. Ambrosini, P. Castellucci, D. Rubello et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl. Med. Commun. 30, 281\u2013286 (2009). \n                    https:\/\/doi.org\/10.1097\/MNM.0b013e32832999c1","journal-title":"Nucl. Med. Commun."},{"key":"1895_CR56","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12020-012-9631-1","volume":"42","author":"G Treglia","year":"2012","unstructured":"G. Treglia, P. Castaldi, G. Rindi, A. Giordano, V. Rufini, Diagnostic performance of Gallium-68 somatostatin receptor PET and PET\/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42, 80\u201387 (2012). \n                    https:\/\/doi.org\/10.1007\/s12020-012-9631-1","journal-title":"Endocrine"},{"key":"1895_CR57","doi-asserted-by":"publisher","first-page":"448","DOI":"10.7150\/thno.3931","volume":"2","author":"K Oberg","year":"2012","unstructured":"K. Oberg, Molecular imaging radiotherapy: theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics 2, 448\u2013458 (2012). \n                    https:\/\/doi.org\/10.7150\/thno.3931","journal-title":"Theranostics"},{"key":"1895_CR58","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2967\/jnumed.109.066639","volume":"50","author":"I Kayani","year":"2009","unstructured":"I. Kayani, B.G. Conry, A.M. Groves et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET\/CT in pulmonary neuroendocrine tumors. J. Nucl. Med. 50, 1927\u20131932 (2009). \n                    https:\/\/doi.org\/10.2967\/jnumed.109.066639","journal-title":"J. Nucl. Med."},{"key":"1895_CR59","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1102\/1470-7330.2011.0010","volume":"11","author":"T Jindal","year":"2011","unstructured":"T. Jindal, A. Kumar, B. Venkitaraman et al. Evaluation of the role of [18F]FDG-PET\/CT and [68Ga]DOTATOC-PET\/CT in differentiating typical and atypical pulmonary carcinoids. Cancer Imaging 11, 70\u201375 (2011). \n                    https:\/\/doi.org\/10.1102\/1470-7330.2011.0010","journal-title":"Cancer Imaging"},{"key":"1895_CR60","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s00259-013-2659-5","volume":"41","author":"B Venkitaraman","year":"2014","unstructured":"B. Venkitaraman, S. Karunanithi, A. Kumar, G.C. Khilnani, R. Kumar, Role of 68Ga-DOTATOC PET\/CT in initial evaluation of patients with suspected bronchopulmonary carcinoid. Eur. J. Nucl. Med. Mol. Imaging 41, 856\u2013864 (2014). \n                    https:\/\/doi.org\/10.1007\/s00259-013-2659-5","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR61","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00259-002-0937-8","volume":"30","author":"N Pandit","year":"2003","unstructured":"N. Pandit, M. Gonen, L. Krug, S.M. Larson, Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging 30, 78\u201384 (2003). \n                    https:\/\/doi.org\/10.1007\/s00259-002-0937-8","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR62","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1159\/000335629","volume":"95","author":"UF Pape","year":"2012","unstructured":"U.-F. Pape, A. Perren, B. Niederle et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 95, 135\u2013156 (2012). \n                    https:\/\/doi.org\/10.1159\/000335629","journal-title":"Neuroendocrinology"},{"key":"1895_CR63","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/bjs.8842","volume":"99","author":"G Capurso","year":"2012","unstructured":"G. Capurso, M. Rinzivillo, R. Bettini, L. Boninsegna, G. Delle Fave, M. Falconi, Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br. J. Surg. 99, 1480\u20131486 (2012). \n                    https:\/\/doi.org\/10.1002\/bjs.8842","journal-title":"Br. J. Surg."},{"key":"1895_CR64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10620-011-1854-0","volume":"57","author":"MD Miljkovi\u0107","year":"2012","unstructured":"M.D. Miljkovi\u0107, M. Girotra, R.R. Abraham, R.B. Erlich, Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. Dig. Dis. Sci. 57, 9\u201318 (2012). \n                    https:\/\/doi.org\/10.1007\/s10620-011-1854-0","journal-title":"Dig. Dis. Sci."},{"key":"1895_CR65","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00259-009-1205-y","volume":"37","author":"V Prasad","year":"2010","unstructured":"V. Prasad, V. Ambrosini, M. Hommann, D. Hoersch, S. Fanti, R.P. Baum, Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET\/CT. Eur. J. Nucl. Med. Mol. Imaging 37, 67\u201377 (2010). \n                    https:\/\/doi.org\/10.1007\/s00259-009-1205-y","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR66","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/RLU.0b013e31823ea730","volume":"37","author":"N Naswa","year":"2012","unstructured":"N. Naswa, P. Sharma, A. Kumar et al. 68Ga-DOTANOC PET\/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin. Nucl. Med. 37, 245\u2013251 (2012). \n                    https:\/\/doi.org\/10.1097\/RLU.0b013e31823ea730","journal-title":"Clin. Nucl. Med."},{"key":"1895_CR67","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1007\/s12149-014-0856-3","volume":"28","author":"O Alonso","year":"2014","unstructured":"O. Alonso, M. Rodr\u00edguez-Taroco, E. Savio, C. Bentancourt, J.P. Gambini, H. Engler, 68)Ga-DOTATATE PET\/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin. Ann. Nucl. Med. 28, 638\u2013645 (2014). \n                    https:\/\/doi.org\/10.1007\/s12149-014-0856-3","journal-title":"Ann. Nucl. Med."},{"key":"1895_CR68","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1007\/s00259-016-3404-7","volume":"43","author":"G Treglia","year":"2016","unstructured":"G. Treglia, C. Aktolun, A. Chiti et al. The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the \u201cevidence-based\u201d refusal to endorse them by EANM due to the \u201cnot evidence-based\u201d marginalization of the role of Nuclear Medicine. Eur. J. Nucl. Med. Mol. Imaging 43, 1486\u20131490 (2016). \n                    https:\/\/doi.org\/10.1007\/s00259-016-3404-7","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR69","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1365-2265.2004.02037.x","volume":"61","author":"S Leboulleux","year":"2004","unstructured":"S. Leboulleux, E. Baudin, J.-P. Travagli, M. Schlumberger, Medullary thyroid carcinoma. Clin. Endocrinol. (Oxf.). 61, 299\u2013310 (2004). \n                    https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02037.x","journal-title":"Clin. Endocrinol. (Oxf.)."},{"key":"1895_CR70","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.1210\/jc.2007-1211","volume":"92","author":"AL Giraudet","year":"2007","unstructured":"A.L. Giraudet, D. Vanel, S. Leboulleux et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J. Clin. Endocrinol. Metab. 92, 4185\u20134190 (2007). \n                    https:\/\/doi.org\/10.1210\/jc.2007-1211","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1895_CR71","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00259-011-2031-6","volume":"39","author":"G Treglia","year":"2012","unstructured":"G. Treglia, P. Castaldi, M.F. Villani et al. Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET\/CT in patients with recurrent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 39, 569\u2013580 (2012). \n                    https:\/\/doi.org\/10.1007\/s00259-011-2031-6","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR72","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1007\/s00259-017-3759-4","volume":"44","author":"AR Romero-Lluch","year":"2017","unstructured":"A.R. Romero-Lluch, J.I. Cuenca-Cuenca, R. Guerrero-V\u00e1zquez et al. Diagnostic utility of PET\/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff. Eur. J. Nucl. Med. Mol. Imaging 44, 2004\u20132013 (2017). \n                    https:\/\/doi.org\/10.1007\/s00259-017-3759-4","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR73","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.2967\/jnumed.112.105940","volume":"53","author":"HHG Verbeek","year":"2012","unstructured":"H.H.G. Verbeek, J.T.M. Plukker, K.P. Koopmans et al. Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma. J. Nucl. Med. 53, 1863\u20131871 (2012). \n                    https:\/\/doi.org\/10.2967\/jnumed.112.105940","journal-title":"J. Nucl. Med."},{"key":"1895_CR74","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12149-017-1213-0","volume":"32","author":"F Caobelli","year":"2018","unstructured":"F. Caobelli, A. Chiaravalloti, L. Evangelista et al. Predictive and prognostic value of 18F-DOPA PET\/CT in patients affected by recurrent medullary carcinoma of the thyroid. Ann. Nucl. Med. 32, 7\u201315 (2018). \n                    https:\/\/doi.org\/10.1007\/s12149-017-1213-0","journal-title":"Ann. Nucl. Med."},{"key":"1895_CR75","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00259-015-3227-y","volume":"43","author":"A Archier","year":"2016","unstructured":"A. Archier, C. Heimburger, C. Guerin et al. 18)F-DOPA PET\/CT in the diagnosis and localization of persistent medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 43, 1027\u20131033 (2016). \n                    https:\/\/doi.org\/10.1007\/s00259-015-3227-y","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR76","first-page":"6647","volume":"34","author":"A Sesti","year":"2014","unstructured":"A. Sesti, M. Mayerhoefer, M. Weber et al. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET. Anticancer Res. 34, 6647\u20136654 (2014)","journal-title":"Anticancer Res."},{"key":"1895_CR77","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2967\/jnumed.111.094771","volume":"52","author":"S Kauhanen","year":"2011","unstructured":"S. Kauhanen, C. Schalin-J\u00e4ntti, M. Sepp\u00e4nen et al. Complementary roles of 18F-DOPA PET\/CT and 18F-FDG PET\/CT in medullary thyroid cancer. J. Nucl. Med. 52, 1855\u20131863 (2011). \n                    https:\/\/doi.org\/10.2967\/jnumed.111.094771","journal-title":"J. Nucl. Med."},{"key":"1895_CR78","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1089\/thy.2009.0342","volume":"20","author":"M Luster","year":"2010","unstructured":"M. Luster, W. Karges, K. Zeich et al. Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography\/computed tomography in the follow-up of medullary thyroid carcinoma. Thyroid 20, 527\u2013533 (2010). \n                    https:\/\/doi.org\/10.1089\/thy.2009.0342","journal-title":"Thyroid"},{"key":"1895_CR79","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ejso.2010.01.001","volume":"36","author":"MC Marzola","year":"2010","unstructured":"M.C. Marzola, M.R. Pelizzo, M. Ferdeghini et al. Dual PET\/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: comparison with conventional imaging. Eur. J. Surg. Oncol. 36, 414\u2013421 (2010). \n                    https:\/\/doi.org\/10.1016\/j.ejso.2010.01.001","journal-title":"Eur. J. Surg. Oncol."},{"key":"1895_CR80","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00330-008-1280-7","volume":"19","author":"M Beheshti","year":"2009","unstructured":"M. Beheshti, S. P\u00f6cher, R. Vali et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur. Radiol. 19, 1425\u20131434 (2009). \n                    https:\/\/doi.org\/10.1007\/s00330-008-1280-7","journal-title":"Eur. Radiol."},{"key":"1895_CR81","doi-asserted-by":"publisher","first-page":"524","DOI":"10.2967\/jnumed.107.047720","volume":"49","author":"KP Koopmans","year":"2008","unstructured":"K.P. Koopmans, J.W.B. de Groot, J.T.M. Plukker et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J. Nucl. Med. 49, 524\u2013531 (2008). \n                    https:\/\/doi.org\/10.2967\/jnumed.107.047720","journal-title":"J. Nucl. Med."},{"key":"1895_CR82","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1007\/s00259-007-0425-2","volume":"34","author":"B Beuthien-Baumann","year":"2007","unstructured":"B. Beuthien-Baumann, A. Strumpf, J. Zessin, J. Bredow, J. Kotzerke, Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 34, 1604\u20131609 (2007). \n                    https:\/\/doi.org\/10.1007\/s00259-007-0425-2","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR83","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s002590000404","volume":"28","author":"S Hoegerle","year":"2001","unstructured":"S. Hoegerle, C. Altehoefer, N. Ghanem, I. Brink, E. Moser, E. Nitzsche, 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur. J. Nucl. Med. 28, 64\u201371 (2001)","journal-title":"Eur. J. Nucl. Med."},{"key":"1895_CR84","doi-asserted-by":"publisher","first-page":"324686","DOI":"10.1155\/2012\/324686","volume":"2012","author":"G Treglia","year":"2012","unstructured":"G. Treglia, V. Rufini, M. Salvatori, A. Giordano, L. Giovanella, PET imaging in recurrent medullary thyroid carcinoma. Int. J. Mol. Imaging 2012, 324686 (2012). \n                    https:\/\/doi.org\/10.1155\/2012\/324686","journal-title":"Int. J. Mol. Imaging"},{"key":"1895_CR85","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/1874471011306020006","volume":"6","author":"K Slavikova","year":"2013","unstructured":"K. Slavikova, F. Montravers, G. Treglia et al. What is currently the best radiopharmaceutical for the hybrid PET\/CT detection of recurrent medullary thyroid carcinoma? Curr. Radiopharm. 6, 96\u2013105 (2013)","journal-title":"Curr. Radiopharm."},{"key":"1895_CR86","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1097\/MNM.0b013e3283543304","volume":"33","author":"M Soussan","year":"2012","unstructured":"M. Soussan, V. Nataf, K. Kerrou et al. Added value of early 18F-FDOPA PET\/CT acquisition time in medullary thyroid cancer. Nucl. Med. Commun. 33, 775\u2013779 (2012). \n                    https:\/\/doi.org\/10.1097\/MNM.0b013e3283543304","journal-title":"Nucl. Med. Commun."},{"key":"1895_CR87","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells","year":"2015","unstructured":"S.A. Wells, S.L. Asa, H. Dralle et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid J. Am. Thyroid Assoc. 25, 567\u2013610 (2015). \n                    https:\/\/doi.org\/10.1089\/thy.2014.0335","journal-title":"Thyroid J. Am. Thyroid Assoc."},{"key":"1895_CR88","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1089\/thy.2008.0403","volume":"19","author":"RT Kloos","year":"2009","unstructured":"American Thyroid Association Guidelines Task Force, R.T. Kloos, C. Eng et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid J. Am. Thyroid Assoc. 19, 565\u2013612 (2009). \n                    https:\/\/doi.org\/10.1089\/thy.2008.0403","journal-title":"Thyroid J. Am. Thyroid Assoc."},{"key":"1895_CR89","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1210\/jc.2007-0938","volume":"92","author":"A Oudoux","year":"2007","unstructured":"A. Oudoux, P.-Y. Salaun, C. Bournaud et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J. Clin. Endocrinol. Metab. 92, 4590\u20134597 (2007). \n                    https:\/\/doi.org\/10.1210\/jc.2007-0938","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1895_CR90","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1210\/jc.2005-0044","volume":"90","author":"J Barbet","year":"2005","unstructured":"J. Barbet, L. Campion, F. Kraeber-Bod\u00e9r\u00e9, J.-F. Chatal; GTE Study Group, Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 90, 6077\u20136084 (2005). \n                    https:\/\/doi.org\/10.1210\/jc.2005-0044","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1895_CR91","unstructured":"K. Pacak, S.H. Tella, Pheochromocytoma and Paraganglioma. ed. by L.J. De Groot, G. Chrousos, K. Dungan et al. Endotext. (MDText.com, Inc., South Dartmouth (MA), 2000). \n                    http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK481899\/\n                    \n                  . Accessed 12 June 2018."},{"key":"1895_CR92","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1210\/jc.2004-1398","volume":"90","author":"L Amar","year":"2005","unstructured":"L. Amar, A. Servais, A.-P. Gimenez-Roqueplo, F. Zinzindohoue, G. Chatellier, P.-F. Plouin, Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J. Clin. Endocrinol. Metab. 90, 2110\u20132116 (2005). \n                    https:\/\/doi.org\/10.1210\/jc.2004-1398","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1895_CR93","unstructured":"R.A. DeLellis, R.V. Lloyd, P.U. Heitz, World Health Organization classification of tumours pathology & genetics. Tumours Endocr. Organs. 151\u2013155 (2004)."},{"key":"1895_CR94","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrendo.2014.188","volume":"11","author":"J Favier","year":"2015","unstructured":"J. Favier, L. Amar, A.-P. Gimenez-Roqueplo, Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat. Rev. Endocrinol. 11, 101\u2013111 (2015). \n                    https:\/\/doi.org\/10.1038\/nrendo.2014.188","journal-title":"Nat. Rev. Endocrinol."},{"key":"1895_CR95","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s00441-018-2791-4","volume":"372","author":"D Ta\u00efeb","year":"2018","unstructured":"D. Ta\u00efeb, K. Pacak, Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. Cell Tissue Res. 372, 393\u2013401 (2018). \n                    https:\/\/doi.org\/10.1007\/s00441-018-2791-4","journal-title":"Cell Tissue Res."},{"key":"1895_CR96","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s00259-012-2215-8","volume":"39","author":"D Ta\u00efeb","year":"2012","unstructured":"D. Ta\u00efeb, H.J. Timmers, E. Hindi\u00e9 et al., EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur. J. Nucl. Med. Mol. Imaging 39, 1977\u20131995 (2012). \n                    https:\/\/doi.org\/10.1007\/s00259-012-2215-8","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"Suppl 7","key":"1895_CR97","doi-asserted-by":"publisher","first-page":"vii110","DOI":"10.1093\/annonc\/mds230","volume":"23","author":"F Pacini","year":"2012","unstructured":"F. Pacini, M.G. Castagna, L. Brilli, G. Pentheroudakis; ESMO Guidelines Working Group, Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(Suppl 7), vii110\u2013vii119 (2012). \n                    https:\/\/doi.org\/10.1093\/annonc\/mds230","journal-title":"Ann. Oncol."},{"key":"1895_CR98","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s00259-012-2087-y","volume":"39","author":"G Treglia","year":"2012","unstructured":"G. Treglia, F. Cocciolillo, C. de Waure et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur. J. Nucl. Med. Mol. Imaging 39, 1144\u20131153 (2012). \n                    https:\/\/doi.org\/10.1007\/s00259-012-2087-y","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR99","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00259-003-1115-3","volume":"30","author":"S Hoegerle","year":"2003","unstructured":"S. Hoegerle, N. Ghanem, C. Altehoefer et al. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur. J. Nucl. Med. Mol. Imaging 30, 689\u2013694 (2003). \n                    https:\/\/doi.org\/10.1007\/s00259-003-1115-3","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR100","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1210\/jc.2009-1248","volume":"94","author":"Timmers HJLM","year":"2009","unstructured":"Timmers HJLM, C.C. Chen, J.A. Carrasquillo et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J. Clin. Endocrinol. Metab. 94, 4757\u20134767 (2009). \n                    https:\/\/doi.org\/10.1210\/jc.2009-1248","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1895_CR101","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2967\/jnumed.115.161018","volume":"57","author":"I Janssen","year":"2016","unstructured":"I. Janssen, C.C. Chen, D. Taieb et al. 68Ga-DOTATATE PET\/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT\/MRI. J. Nucl. Med. 57, 186\u2013191 (2016). \n                    https:\/\/doi.org\/10.2967\/jnumed.115.161018","journal-title":"J. Nucl. Med."},{"key":"1895_CR102","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s00259-015-3268-2","volume":"43","author":"A Archier","year":"2016","unstructured":"A. Archier, A. Varoquaux, P. Garrigue et al. Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET\/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases. Eur. J. Nucl. Med. Mol. Imaging 43, 1248\u20131257 (2016). \n                    https:\/\/doi.org\/10.1007\/s00259-015-3268-2","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR103","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1007\/s00259-013-2548-y","volume":"40","author":"A Kroiss","year":"2013","unstructured":"A. Kroiss, D. Putzer, A. Frech et al. A retrospective comparison between 68Ga-DOTA-TOC PET\/CT and 18F-DOPA PET\/CT in patients with extra-adrenal paraganglioma. Eur. J. Nucl. Med. Mol. Imaging 40, 1800\u20131808 (2013). \n                    https:\/\/doi.org\/10.1007\/s00259-013-2548-y","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR104","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","volume":"21","author":"I Janssen","year":"2015","unstructured":"I. Janssen, E.M. Blanchet, K. Adams et al. Superiority of [68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma. Clin. Cancer Res. 21, 3888\u20133895 (2015). \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2751","journal-title":"Clin. Cancer Res."},{"key":"1895_CR105","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00259-015-3003-z","volume":"42","author":"C Lepoutre-Lussey","year":"2015","unstructured":"C. Lepoutre-Lussey, C. Caramella, F. Bidault et al. Screening in asymptomatic SDHx mutation carriers: added value of 18F-FDG PET\/CT at initial diagnosis and 1-year follow-up. Eur. J. Nucl. Med. Mol. Imaging 42, 868\u2013876 (2015). \n                    https:\/\/doi.org\/10.1007\/s00259-015-3003-z","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR106","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0140-6736(17)31430-7","volume":"391","author":"JP Bilezikian","year":"2018","unstructured":"J.P. Bilezikian, L. Bandeira, A. Khan, N.E. Cusano, Hyperparathyroidism. Lancet Lond. Engl. 391, 168\u2013178 (2018). \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)31430-7","journal-title":"Lancet Lond. Engl."},{"key":"1895_CR107","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1210\/jc.2014-1413","volume":"99","author":"JP Bilezikian","year":"2014","unstructured":"J.P. Bilezikian, M.L. Brandi, R. Eastell et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3561\u20133569 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2014-1413","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1895_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-016-3716-2","volume":"28","author":"AA Khan","year":"2017","unstructured":"A.A. Khan, D.A. Hanley, R. Rizzoli et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos. Int J. Establ Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA 28, 1\u201319 (2017). \n                    https:\/\/doi.org\/10.1007\/s00198-016-3716-2","journal-title":"Osteoporos. Int J. Establ Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA"},{"key":"1895_CR109","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.soc.2015.08.012","volume":"25","author":"AM Laird","year":"2016","unstructured":"A.M. Laird, S.K. Libutti, Minimally invasive parathyroidectomy versus bilateral neck exploration for primary hyperparathyroidism. Surg. Oncol. Clin. N. Am. 25, 103\u2013118 (2016). \n                    https:\/\/doi.org\/10.1016\/j.soc.2015.08.012","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"1895_CR110","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.otohns.2004.10.005","volume":"132","author":"JM Ruda","year":"2005","unstructured":"J.M. Ruda, C.S. Hollenbeak, B.C. Stack, A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol. Head Neck Surg. 132, 359\u2013372 (2005). \n                    https:\/\/doi.org\/10.1016\/j.otohns.2004.10.005","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"1895_CR111","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.amjsurg.2006.04.020","volume":"193","author":"CY Lo","year":"2007","unstructured":"C.-Y. Lo, B.H. Lang, W.F. Chan, A.W.C. Kung, K.S.L. Lam, A prospective evaluation of preoperative localization by technetium-99m sestamibi scintigraphy and ultrasonography in primary hyperparathyroidism. Am. J. Surg. 193, 155\u2013159 (2007). \n                    https:\/\/doi.org\/10.1016\/j.amjsurg.2006.04.020","journal-title":"Am. J. Surg."},{"key":"1895_CR112","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3413\/nukmed-0108","volume":"47","author":"C Ansquer","year":"2008","unstructured":"C. Ansquer, E. Miralli\u00e9, T. Carlier, H. Abbey-Huguenin, F. Aubron, F. Kraeber-Bod\u00e9r\u00e9, Preoperative localization of parathyroid lesions. Value of 99mTc-MIBI tomography and factors influencing detection. Nukl. Nucl. Med. 47, 158\u2013162 (2008)","journal-title":"Nukl. Nucl. Med."},{"key":"1895_CR113","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00259-007-0625-9","volume":"35","author":"T Carlier","year":"2008","unstructured":"T. Carlier, A. Oudoux, E. Miralli\u00e9 et al. 99mTc-MIBI pinhole SPECT in primary hyperparathyroidism: comparison with conventional SPECT, planar scintigraphy and ultrasonography. Eur. J. Nucl. Med. Mol. Imaging 35, 637\u2013643 (2008). \n                    https:\/\/doi.org\/10.1007\/s00259-007-0625-9","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR114","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1097\/RLU.0b013e3182a77b62","volume":"39","author":"T Cazaentre","year":"2014","unstructured":"T. Cazaentre, F. Clivaz, F. Triponez, False-positive result in 18F-fluorocholine PET\/CT due to incidental and ectopic parathyroid hyperplasia. Clin. Nucl. Med. 39, e328\u2013e330 (2014). \n                    https:\/\/doi.org\/10.1097\/RLU.0b013e3182a77b62","journal-title":"Clin. Nucl. Med."},{"key":"1895_CR115","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2478\/raon-2013-0075","volume":"48","author":"M Hodolic","year":"2014","unstructured":"M. Hodolic, V. Huchet, S. Balogova et al. Incidental uptake of (18)F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. Radiol. Oncol. 48, 228\u2013234 (2014). \n                    https:\/\/doi.org\/10.2478\/raon-2013-0075","journal-title":"Radiol. Oncol."},{"key":"1895_CR116","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/RLU.0b013e31824c5ffc","volume":"37","author":"P Mapelli","year":"2012","unstructured":"P. Mapelli, E. Busnardo, P. Magnani et al. Incidental finding of parathyroid adenoma with 11C-choline PET\/CT. Clin. Nucl. Med. 37, 593\u2013595 (2012). \n                    https:\/\/doi.org\/10.1097\/RLU.0b013e31824c5ffc","journal-title":"Clin. Nucl. Med."},{"key":"1895_CR117","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1097\/RLU.0000000000000607","volume":"39","author":"M Orevi","year":"2014","unstructured":"M. Orevi, N. Freedman, E. Mishani, M. Bocher, O. Jacobson, Y. Krausz, Localization of parathyroid adenoma by 11C-choline PET\/CT: preliminary results. Clin. Nucl. Med. 39, 1033\u20131038 (2014). \n                    https:\/\/doi.org\/10.1097\/RLU.0000000000000607","journal-title":"Clin. Nucl. Med."},{"key":"1895_CR118","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1007\/s00259-014-2837-0","volume":"41","author":"L Lezaic","year":"2014","unstructured":"L. Lezaic, S. Rep, M.J. Sever, T. Kocjan, M. Hocevar, J. Fettich, 18F-Fluorocholine PET\/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study. Eur. J. Nucl. Med. Mol. Imaging 41, 2083\u20132089 (2014). \n                    https:\/\/doi.org\/10.1007\/s00259-014-2837-0","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR119","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejso.2016.09.016","volume":"43","author":"M Hocevar","year":"2017","unstructured":"M. Hocevar, L. Lezaic, S. Rep et al. Focused parathyroidectomy without intraoperative parathormone testing is safe after pre-operative localization with 18F-Fluorocholine PET\/CT. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 43, 133\u2013137 (2017). \n                    https:\/\/doi.org\/10.1016\/j.ejso.2016.09.016","journal-title":"Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol."},{"key":"1895_CR120","doi-asserted-by":"publisher","first-page":"e491","DOI":"10.1097\/RLU.0000000000001845","volume":"42","author":"N Thanseer","year":"2017","unstructured":"N. Thanseer, S.K. Bhadada, A. Sood et al. Comparative effectiveness of ultrasonography, 99mTc-Sestamibi, and 18F-Fluorocholine PET\/CT in detecting parathyroid adenomas in patients with primary hyperparathyroidism. Clin. Nucl. Med. 42, e491\u2013e497 (2017). \n                    https:\/\/doi.org\/10.1097\/RLU.0000000000001845","journal-title":"Clin. Nucl. Med."},{"key":"1895_CR121","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1088\/1361-6498\/aaa86f","volume":"38","author":"S Rep","year":"2018","unstructured":"S. Rep, M. Hocevar, J. Vaupotic, U. Zdesar, K. Zaletel, L. Lezaic, 18F-choline PET\/CT for parathyroid scintigraphy: significantly lower radiation exposure of patients in comparison to conventional nuclear medicine imaging approaches. J. Radiol. Prot. 38, 343\u2013356 (2018). \n                    https:\/\/doi.org\/10.1088\/1361-6498\/aaa86f","journal-title":"J. Radiol. Prot."},{"key":"1895_CR122","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00423-010-0724-0","volume":"396","author":"AOJ Bergenfelz","year":"2011","unstructured":"A.O.J. Bergenfelz, G. Wallin, S. Jansson et al. Results of surgery for sporadic primary hyperparathyroidism in patients with preoperatively negative sestamibi scintigraphy and ultrasound. Langenbecks Arch. Surg. 396, 83\u201390 (2011). \n                    https:\/\/doi.org\/10.1007\/s00423-010-0724-0","journal-title":"Langenbecks Arch. Surg."},{"key":"1895_CR123","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1245\/s10434-012-2325-3","volume":"19","author":"BM Dy","year":"2012","unstructured":"B.M. Dy, M.L. Richards, B.J. Vazquez, G.B. Thompson, D.R. Farley, C.S. Grant, Primary hyperparathyroidism and negative Tc99 sestamibi imaging: to operate or not? Ann. Surg. Oncol. 19, 2272\u20132278 (2012). \n                    https:\/\/doi.org\/10.1245\/s10434-012-2325-3","journal-title":"Ann. Surg. Oncol."},{"key":"1895_CR124","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1210\/jc.2014-2821","volume":"99","author":"L Michaud","year":"2014","unstructured":"L. Michaud, A. Burgess, V. Huchet et al. Is 18F-fluorocholine-positron emission tomography\/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J. Clin. Endocrinol. Metab. 99, 4531\u20134536 (2014). \n                    https:\/\/doi.org\/10.1210\/jc.2014-2821","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1895_CR125","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001701","volume":"94","author":"L Michaud","year":"2015","unstructured":"L. Michaud, S. Balogova, A. Burgess et al. A pilot comparison of 18F-fluorocholine PET\/CT, ultrasonography and 123I\/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine (Baltimore) 94, e1701 (2015). \n                    https:\/\/doi.org\/10.1097\/MD.0000000000001701","journal-title":"Medicine (Baltimore)"},{"key":"1895_CR126","doi-asserted-by":"publisher","unstructured":"S. Grimaldi, J. Young, P. Kamenicky et al., Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of 18F-Fluorocholine PET\/CT. Eur. J. Nucl. Med. Mol. Imaging. (2018). \n                    https:\/\/doi.org\/10.1007\/s00259-018-4018-z","DOI":"10.1007\/s00259-018-4018-z"},{"key":"1895_CR127","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1515\/raon-2015-0016","volume":"49","author":"S Rep","year":"2015","unstructured":"S. Rep, L. Lezaic, T. Kocjan et al. Optimal scan time for evaluation of parathyroid adenoma with [(18)F]-fluorocholine PET\/CT. Radiol. Oncol. 49, 327\u2013333 (2015). \n                    https:\/\/doi.org\/10.1515\/raon-2015-0016","journal-title":"Radiol. Oncol."},{"key":"1895_CR128","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1097\/MNM.0000000000000595","volume":"37","author":"WP Kluijfhout","year":"2016","unstructured":"W.P. Kluijfhout, W.M.C.M. Vorselaars, S.A.M. van den Berk et al. Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: a multicenter study from the Netherlands. Nucl. Med. Commun. 37, 1246\u20131252 (2016). \n                    https:\/\/doi.org\/10.1097\/MNM.0000000000000595","journal-title":"Nucl. Med. Commun."},{"key":"1895_CR129","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1148\/radiol.2016160768","volume":"284","author":"WP Kluijfhout","year":"2017","unstructured":"W.P. Kluijfhout, J.D. Pasternak, J.E. Gosnell et al. 18F fluorocholine PET\/MR imaging in patients with primary hyperparathyroidism and inconclusive conventional imaging: a prospective pilot study. Radiology 284, 460\u2013467 (2017). \n                    https:\/\/doi.org\/10.1148\/radiol.2016160768","journal-title":"Radiology"},{"key":"1895_CR130","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1007\/s00259-017-3911-1","volume":"45","author":"E Quak","year":"2018","unstructured":"E. Quak, D. Blanchard, B. Houdu et al. F18-choline PET\/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT\/CT are negative or inconclusive: the APACH1 study. Eur. J. Nucl. Med. Mol. Imaging 45, 658\u2013666 (2018). \n                    https:\/\/doi.org\/10.1007\/s00259-017-3911-1","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR131","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1007\/s00259-018-3980-9","volume":"45","author":"M Beheshti","year":"2018","unstructured":"M. Beheshti, L. Hehenwarter, Z. Paymani et al. 18F-Fluorocholine PET\/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT\/CT: a prospective dual-centre study in 100 patients. Eur. J. Nucl. Med. Mol. Imaging 45, 1762\u20131771 (2018). \n                    https:\/\/doi.org\/10.1007\/s00259-018-3980-9","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1895_CR132","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3389\/fendo.2017.00380","volume":"8","author":"S Fischli","year":"2017","unstructured":"S. Fischli, I. Suter-Widmer, B.T. Nguyen et al. The significance of 18F-Fluorocholine-PET\/CT as localizing imaging technique in patients with primary hyperparathyroidism and negative conventional imaging. Front. Endocrinol. 8, 380 (2017). \n                    https:\/\/doi.org\/10.3389\/fendo.2017.00380","journal-title":"Front. Endocrinol."},{"key":"1895_CR133","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1007\/s00330-017-5190-4","volume":"28","author":"GF Huber","year":"2018","unstructured":"G.F. Huber, M. H\u00fcllner, C. Schmid et al. Benefit of 18F-fluorocholine PET imaging in parathyroid surgery. Eur. Radiol. 28, 2700\u20132707 (2018). \n                    https:\/\/doi.org\/10.1007\/s00330-017-5190-4","journal-title":"Eur. Radiol."},{"key":"1895_CR134","doi-asserted-by":"publisher","unstructured":"C. Amadou, G. Bera, M. Ezziane et al., 18F-Fluorocholine PET\/CT and parathyroid 4D computed tomography for primary hyperparathyroidism: the challenge of reoperative patients. World J. Surg. (2019). \n                    https:\/\/doi.org\/10.1007\/s00268-019-04910-6","DOI":"10.1007\/s00268-019-04910-6"},{"key":"1895_CR135","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1530\/EJE-16-0639","volume":"175","author":"O Koulouri","year":"2016","unstructured":"O. Koulouri, N. Kandasamy, A.C. Hoole et al. Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI. Eur. J. Endocrinol. 175, 485\u2013498 (2016). \n                    https:\/\/doi.org\/10.1530\/EJE-16-0639","journal-title":"Eur. J. Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-01895-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-019-01895-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-019-01895-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:40:58Z","timestamp":1584060058000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-019-01895-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":135,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1895"],"URL":"https:\/\/doi.org\/10.1007\/s12020-019-01895-z","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"13 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients signed an inform consent stipulating that their images could be used in a research context after anonymized.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}